9 news items
Tesla, Nvidia, John Wiley & Sons And Other Big Stocks Moving Higher On Thursday
ACLS
AMSC
ANET
13 Jun 24
the price target from $20 to $27.
Broadcom Inc
HC Wainwright & Co. Reiterates Buy on Verona Pharma, Maintains $32 Price Target
VRNA
15 May 24
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Verona Pharma (NASDAQ:VRNA) with a Buy and maintains $32 price target.
HC Wainwright & Co. Maintains Buy on Verona Pharma, Lowers Price Target to $30
VRNA
13 May 24
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Verona Pharma (NASDAQ:VRNA) with a Buy and lowers the price target from $33 to $30.
Verona Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
VRNA
9 May 24
PDUFA Target Action Date
Verona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERS
HTGC
VRNA
9 May 24
and assigned a PDUFA target action date of June 26, 2024. If approved, ensifentrine has the potential to become the first inhaled non-steroidal therapy
cz8qme68u8 gd8bpyj2t
VRNA
2 May 24
PDUFA Target Action Date of June 26, 2024
Eight posters including two oral presentations support potential of ensifentrine, an investigational, first-in-class, selective, dual inhibitor of PDE3 and PDE4
9iwzoepookcrz2auk065aom0h7ti2ceb7s11v
VRNA
2 May 24
PDUFA Target Action Date
ou4f3l8gae7 2bmt3za
VRNA
25 Apr 24
and assigned a PDUFA target action date of June 26, 2024. If approved, ensifentrine has the potential to become the first non-steroidal therapy
3s20ml3b
VRNA
16 Apr 24
Piper Sandler analyst Yasmeen Rahimi maintains Verona Pharma (NASDAQ:VRNA) with a Overweight and raises the price target from $31 to $36.
- Prev
- 1
- Next